Scarica l'app Stockscreener
3.735
6.41%
0.225
Precedente Chiudi:
$3.51
Aprire:
$3.53
Volume 24 ore:
2.55M
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.22B
Reddito:
$7.47M
Utile/perdita netta:
$-129.88M
Rapporto P/E:
-9.4271
EPS:
-0.3962
Flusso di cassa netto:
$-115.33M
1 W Prestazione:
-15.69%
1M Prestazione:
-26.19%
6M Prestazione:
-37.75%
1 anno Prestazione:
-30.06%
Intervallo 1D:
$3.50
$3.79
Intervallo di 1 settimana:
$3.455
$4.565
Portata 52W:
$3.455
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
3.735 | 1.22B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.88 | 94.97B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.50 | 82.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.70 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-17 | Iniziato | Wolfe Research | Outperform |
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more. - Stock Titan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha
These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo
Certain Common Stock of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - www.marketscreener.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownShould You Sell? - MarketBeat
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st
Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest TradingAnalyst Drop Coverage - vinanet.vn
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo
Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69Bull Flag - Vinanet
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - stocktitan.net
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia
Why is Taysha Gene Therapies stock sliding today? - Investing.com
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com India
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Canada
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
Taysha Gene Therapies Q2 2026 Earnings Call Transcript - MarketBeat
TSHA Looks 873.5% Overvalued on GF Value™ - GuruFocus
Taysha Gene Therapies Q2 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies Q2 Earnings Call Highlights - TradingView
Taysha Gene Therapies Q2 Earnings Call Highlights - Yahoo Finance
TSHA: Completed pivotal trial dosing, secured $230M financing, and advanced toward BLA submission - TradingView
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast - Investing.com
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million - scanx.trade
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss - marketscreener.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Therapies Q2 net loss widens on higher R&D costs - TradingView
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Taysha Gene faces earnings test as Rett therapy advances By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Taysha Gene Therapies Inc Azioni (TSHA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | Officer |
Jul 10 '26 |
Proposed Sale |
6.49 |
200,000 |
1,298,000 |
0 |
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Option Exercise |
1.71 |
19,021 |
32,526 |
1,336,410 |
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
| Nagendran Sukumar | Officer |
Apr 10 '26 |
Proposed Sale |
4.63 |
200,000 |
926,000 |
0 |
| Rumana Haque-Ahmed | Officer |
Feb 27 '26 |
Proposed Sale |
4.57 |
2,405 |
10,991 |
0 |
| Sean McAuliffe | Affiliate - Chief Business Off |
Feb 04 '26 |
Proposed Sale |
4.72 |
914 |
4,314 |
0 |
| Kamran Alam | Officer |
Feb 04 '26 |
Proposed Sale |
4.72 |
1,655 |
7,812 |
0 |
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
4.52 |
1,655 |
7,481 |
1,442,131 |
| Emily McGinnis | Affiliate-Chief Pat. Adv. & |
Feb 04 '26 |
Proposed Sale |
4.72 |
901 |
4,253 |
0 |
| Fred Porter | Affiliate-Chief of Staff & |
Feb 04 '26 |
Proposed Sale |
4.72 |
889 |
4,196 |
0 |
0.04%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):